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Purpose
Assessment of safety of rituximab in children with auto-
immune diseases (AID) in published reports.
Methods
Pooled analysis of the literature using the Medline data-
base until March 2008.
Results
We identified 169 children treated for refractory AID:
autoimmune cytopenia (s) (104 patients), systemic lupus
erythematosus (SLE) (52 patients), miscellaneous (13
patients). The mean follow-up period was 6 to 36 months.
Patients received 2 to 4 rituximab infusions (350–750
mg/m2) associated with immunosuppressive drugs in 49/
52 SLE patients. Replacement intravenous immunoglobu-
lins therapy was given to 68/169 patients. Moderate side
effects were observed in 50/169 patients: infusion-related
reactions, infections, transient neutropenia > 0.5 × 109/L
and serum sickness disease. Severe side effects were
observed after rituximab infusion in 11/169 (6.6%)
patients: severe infusion related hypotention (4 patients),
neutropenia < 0.2 × 109/L (3 patients), (2 SLE patients),
cerebral vasculitis (1 SLE patient). Two SLE patients who
have received cyclophosphamide died from cerebral his-
toplasmosis and Staphyloccoccus aureus endocarditis, and
one boy who underwent autologous bone marrow trans-
plantation for severe thrombocytopenic purpura devel-
oped severe enteroviral meningoencephalitis ; Ig G level
was low at time of infection in 3/4 patients and not avail-
able in the fifth.
Conclusion
Severe adverse events were recorded in 6.6% of the rituxi-
mab-treated children. Patients who have received previ-
ous, concurrent and/or subsequent immunosuppressive
drugs may experience severe infections, and must be
closely monitored. A cohort study of children treated for
auto-immune diseases with rituximab has been initiated
in France since March 2008 to better assess the tolerance
of this therapy.
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